Regulation of μ-opioid receptor in neural cells by extracellular sodium

Journal of Neurochemistry

Volumn 68, Issue 3, 1997, Pages 1053-1061

  Yabaluri, Nirmala ^a   Medzihradsky, Fedor ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Amiloride; Cyclic AMP; Monensin; Opioid receptor; Potassium; Sodium

Indexed keywords

5 (N ETHYL N ISOPROPYL)AMILORIDE; ADENYLATE CYCLASE; CHOLINE; CYCLIC AMP; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; FORSKOLIN; MONENSIN; MU OPIATE RECEPTOR; NALTREXONE; OUABAIN; POTASSIUM CHLORIDE; SODIUM ION;

ARTICLE; CONTROLLED STUDY; DISSOCIATION CONSTANT; ENZYME INHIBITION; HUMAN; HUMAN CELL; LIGAND BINDING; NEUROBLASTOMA CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SODIUM CELL LEVEL;

STROPHANTHUS GRATUS;

EID: 0031034179     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.1997.68031053.x     Document Type: Article

References (42)

1. + and GTP. Proc. Natl. Acad. Sci. USA 76, 5626-5630.
2. Carter B. D. and Medzihradsky F. (1992) Opioid signal transduction in intact and fragmented SH-SY5Y neural cells. J. Neurochem. 58, 1611-1619.
3. 2 adrenergic receptor system of human platelets. J. Biol. Chem. 258, 3907-3912.
4. Costa T., Lang J., and Herz A. (1989) Spontaneous association between opioid receptors and GTP-binding regulatory proteins in native membranes: specific regulation by antagonists and sodium ions. Mol. Pharmacol. 37, 383-394.
5. Feinberg H., Sandler W. C., Scorer M., Le Breton G. C., Grossman B., and Born G. V. R. (1977) Movement of sodium into human platelets induced by ADP. Biochim. Biophys. Acta 470, 317-324.
6. Fischel S. V. and Medzihradsky F. (1981) Scatchard analysis of opiate receptor binding. Mol. Pharmacol. 20, 269-279.
7. Fozzard H. A. and Kipnis D. M. (1967) Regulation of intracellular sodium concentrations in rat diaphragm muscle. Science 156, 1257-1260.
8. 1 muscarinic acetylcholine receptors: conserved aspartic acids play important roles in receptor function. Mol. Pharmacol. 36, 840-847.
9. Green D. A. and Clark R. B. (1982) Direct evidence for the role of the coupling proteins in forskolin activation of adenylate cyclase. J. Cyclic Nucleotide Res. 8, 337-346.
10. Harris E. J. and Pressman B. C. (1965) Obligate cation exchanges in red cells. Nature 216, 918-920.
11. + exchange in neuroblastoma-glioma cells via a mechanism other than decreased cAMP accumulation. J. Biol. Chem. 262, 17504-17509.
12. +, 5′-guanylimidophosphate, amiloride and ethylisopropyl amiloride: evidence for receptor G-protein precoupling. J. Pharmacol. Exp. Ther. 252, 1184-1196.
13. Jakobs K. (1979) Inhibition of adenylate cyclase by hormones and neurotransmitters. Mol. Cell. Endocrinol. 16, 147-156.
14. Ji I. and Ji T. H. (1991) Asp 383 in the second transmembrane domain of the lutropin receptor is important for high affinity hormone binding and cAMP production. J. Biol. Chem. 266, 14953-14957.
15. + regulation of agonist binding but does not alter receptor-G protein association. Mol. Pharmacol. 44, 380-384.
16. Kong H., Raynor K., Yasuda K., Moe S. T., Portoghese P. S., Bell G. I., and Reisine T. (1993b) A single residue, aspartic acid 95, in the δ opioid receptor specifies selective high affinity agonist binding. J. Biol. Chem. 268, 23055-23058.
17. Kong H., Raynor K., Yano H., Takeda J., Bell G. I., and Reisine T. (1994) Agonists and antagonists bind to different domains of the cloned κ opioid receptor. Proc. Natl. Acad. Sci. USA 91, 8042-8046.
18. Lazar D. F. and Medzihradsky F. (1993) Altered transition between agonist- and antagonist-favoring states of μ-opioid receptor in brain membranes with modified microviscosity. J. Neurochem. 61, 1135-1140.
19. + for the regulation of cAMP levels in intact NG108-15 cells. Life Sci. 25, 985-992.
20. Lowry O. H., Rosebrough N. J., Farr A. L., and Randall R. J. (1951) Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193, 265-275.
21. + and guanine nucleotides. Nature 288, 709-711.
22. 2-adrenergic receptor system of human platelets: role for intraplatelet sodium in receptor binding. J. Biol. Chem. 258, 3913-3919.
23. 125I-epidepride, a high affinity substituted benzamide ligand. J. Pharmacol. Exp. Ther. 252, 1108-1116.
24. Nijssen P. C. G. and Childers S. R. (1987) Characteristics of sodium-induced increase in opiate antagonist binding sites in rat brain membranes. Eur. J. Pharmacol. 135, 355-364.
25. + exchange. J. Biol. Chem. 262, 12387-12392.
26. Pacheco M. A., Ward S. J., and Childers S. R. (1994) Differential requirements of sodium for coupling of cannabinoid receptors to adenylyl cyclase in rat brain membranes. J. Neurochem. 62, 1773-1782.
27. Pert C. B. and Snyder S. H. (1976) Opiate receptor binding of agonists and antagonists affected differentially by sodium. Mol. Pharmacol. 10, 868-879.
28. Pert C. B., Pasternak G., and Snyder S. H. (1973) Opiate agonists and antagonists discriminated by receptor binding in rat brain. Science 182, 1349-1351.
29. Puttfarcken P., Werling L. L., Brown S. R., Cote T. E., and Cox B. M. (1986) Sodium regulation of agonist binding at opioid receptors. Effects of sodium replacement on binding at μ- and δ-type receptors in 7315c and NG108-15 cells and cell membranes. Mol. Pharmacol. 30, 81-89.
30. + potentiometry: relationship with antimicrobial and antimalarial activities. J. Med. Chem. 39, 588-595.
31. Seamon K. B., Padgett H., and Daly J. W. (1981) Forskolin: unique diterpene activator of adenylate cyclase in membranes and in intact cells. Proc. Natl. Acad. Sci. USA 78, 3363-3367.
32. Simon E. J., Hiller J. M., Groth J., and Edelman I. (1975) Further properties of stereospecific opiate binding sites in rat brain: on the nature of the sodium effect. J. Pharmacol. Exp. Ther. 192, 531-537.
33. Strader C. D., Sigal I. S., Candelore M. R., Rands E., Hill W. S., and Dixon R. A. F. (1988) Conserved aspartic acid residues 79 and 113 of the beta-adrenergic receptor have different roles in receptor function. J. Biol. Chem. 263, 10267-10271.
34. Surratt C. K., Johnson P. S., Moriwaki A., Seidleck B. K., Blaschak C. J., Wang J. B., and Uhl G. R. (1994) μ-Opiate receptor. J. Biol. Chem. 269, 20548-20553.
35. 2-adrenergic receptor. Mol. Pharmacol. 34, 814-822.
36. Toll L. (1992) Comparison of mu opioid receptor binding on intact neuroblastoma cells with guinea pig brain and neuroblastoma cell membranes. J. Pharmacol. Exp. Ther. 260, 9-15.
37. + exchange system in various cell types. Biochem. Biophys. Res. Commun. 116, 86-90.
38. 2A-adrenergic receptors: identification of amino acids involved in ligand binding and receptor activation by agonists. Mol. Pharmacol. 40, 168-179.
39. Werling L. L., Brown S. R., Puttfarcken P., and Cox B. M. (1986) Sodium regulation of agonist binding at opioid receptors. Effects of sodium replacement on opioid binding in guinea pig cortical membranes. Mol. Pharmacol. 30, 90-95.
40. Werling L. L., Puttfarcken P. S., and Cox B. M. (1988) Multiple agonist-affinity states of opioid receptors: regulation of binding by guanyl nucleotides in guinea pig cortical, NG108-15, and 7315c cell membranes. Mol. Pharmacol. 33, 423-431.
41. Wilkinson L. (1988) SYSTAT: The System for Statistics. SYSTAT, Evanston, Illinois.
42. Yabaluri N. and Medzihradsky F. (1995) Reversible modulation of opioid receptor binding in intact neural cells by endogenous guanosine triphosphate. Mol. Pharmacol. 48, 690-695.